Rein Therapeutics Inc. Ordinary Shares RNTX 深 滬
已收盤 10-10 16:00:00 美东时间
1.30
-0.070
-5.11%
華盛通- 最 高1.3805
- 今 開1.36
- 成交量 6.12万股
- 最 低 1.28
- 昨 收 1.37
- 總市值 2879.98万
- 52周最高 4.40
- 市盈率 靜 --
- 換手率 0.28%
- 52周最低 1.04
- 委 比 36.67%
- 總股本 2215.37万
- 歷史最高 309.60
- 量 比 0.34
- 振 幅 7.34%
- 歷史最低 1.01
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
Rein Therapeutics announced the publication of new data on LTI-03 in *iScience*, showing its potential as a breakthrough anti-fibrotic therapy for idiopathic pulmonary fibrosis (IPF). Tested on lung tissue from IPF patients, LTI-03 demonstrated reduction in scarring and inflammation, while avoiding cell damage. Unlike nintedanib, a current standard-of-care drug, LTI-03’s safety profile is strong. These findings support Rein’s Phase 2 RENEW trial,...
09-17 11:30
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 38.2% to $2.86 dur...
09-05 01:05
Brookline Capital Downgrades Rein Therapeutics to Hold
Brookline Capital analyst Kemp Dolliver downgrades Rein Therapeutics (NASDAQ:RNTX) from Buy to Hold.
08-19 22:17
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics has received UK MHRA approval to initiate a Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF), a deadly lung disease. LTI-03 aims to target fibrosis and protect lung regeneration. The RENEW trial will enroll up to 120 global patients to assess safety, tolerability, and efficacy. Initial data expected in 2026.
08-19 12:00
Aileron Therapeutics Q2 EPS $(0.28) Misses $(0.22) Estimate
Aileron Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 37.78 percent increase over losses of $(0.45) per share
08-15 04:14
Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
Rein Therapeutics announced that its Chief Scientific Officer, Dr. Cory Hogaboam, and Chief Executive Officer, Dr. Brian Windsor, will present at the IPF Summit 2025 in Boston. Dr. Hogaboam will discuss the role of lung-resident macrophages in IPF and how Caveolin-scaffolding domain (CSD) peptides may target fibrosis drivers. Dr. Windsor will present on Rein's Phase 2 trial of LTI-03, focusing on safety, tolerability, and lung function outcomes. ...
08-14 21:00
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration
Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 6, 2025 /PRNewswir...
08-07 07:56
Rein Therapeutics Enters Into Two Strategic Financing Agreements With Affiliate Of Yorkville Advisors Global, Providing Potential For Access To Up To $21M In Capital
Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications,
07-30 20:34
